This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
by Kinjel Shah
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
by Zacks Equity Research
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
by Zacks Equity Research
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
by Zacks Equity Research
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session.
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
by Zacks Equity Research
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Procter & Gamble, Adobe, Advanced Micro Devices and AstraZeneca
by Zacks Equity Research
Berkshire Hathaway, Procter & Gamble, Adobe, Advanced Micro Devices and AstraZeneca are included in this Analyst Blog.
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
by Zacks Equity Research
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Top Research Reports for Berkshire Hathaway, Procter & Gamble & Adobe
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Procter & Gamble Company (PG) and Adobe Inc. (ADBE).
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
by Zacks Equity Research
AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $67.25, signifying a -0.74% move from its prior day's close.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
by Kinjel Shah
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.